Rutherford Health - New Proton Beam Therapy Centre in Berkshire London Stock Exchange
RNS Number : 5324J
Rutherford Health PLC
19 August 2019

19 August 2019


Rutherford Health Plc


Rutherford Health Plc is delighted to announce that as anticipated, its centre in Reading, Berkshire, the Rutherford Cancer Centre Thames Valley, has today officially opened its new proton beam therapy suite to meet growing demand for the pioneering treatment.

The centre in Reading, Berkshire, just 25 minutes from Central London, is the first such facility in South East England and will serve all of London as well as international patients.

The Centre is part of a network of Rutherford Cancer Centres which have three fully operational centres in Wales, Northumberland and now Reading which, together with an NHS facility in Manchester, have transformed the landscape for advanced cancer care in the UK.

The Thames Valley centre also enjoys a permanent consultation facility in London's Harley Street, which will allow patients to have their consultations in London before receiving treatment at the Thames Valley centre. The centre has started treating its first patients with proton beam therapy.

Proton beam therapy is a type of radiotherapy that delivers heavily charged protons in a more targeted manner to reduce damage to peripheral tissue and organs. Its accuracy means that it can help reduce unwelcome side effects.

Professor Karol Sikora, chief medical officer of Rutherford Health Plc which operates the Rutherford Cancer Centres, said: "UK cancer care has made major strides over the past year thanks to a complementary mix of private and public facilities but rising demand for precision radiotherapy means that there is still some way to go. Based on treatment rates in other advanced European countries, the UK may need approximately 18 proton beam therapy facilities in the years to come."

Mike Moran, chief executive of Rutherford Health Plc, said: "The opening of our latest proton beam therapy suite marks a major milestone for advanced cancer care in the UK. It is remarkable that just over a year ago, there were no such facilities in the UK. Patients who needed proton beam therapy had to travel abroad which involves considerable cost and inconvenience, we now have three centres with more on the way. It reflects the rising demand for proton beam therapy and we are determined to ensure cancer patients can receive the treatment that they need without facing any delays or having to travel abroad."

Each Rutherford Cancer Centre provides imaging, chemotherapy, immunotherapy, radiotherapy, and proton beam therapy as well as a suite of diagnostic services. A fourth Rutherford Cancer Centre is currently under construction in Liverpool.   

Laura Geer, centre manager of Rutherford Cancer Centre Thames Valley, said: "Bringing advanced cancer treatments to the most populous region of the UK and the biggest city in Europe for the first time will have a major impact on patient outcomes and help transform cancer care nationally."

"Our permanent presence in Harley Street means that patients can receive their initial consultations in Central London before receiving treatment at Thames Valley just a 25-minute train journey away. This is ideal for international patients and patients who live in London and will play a crucial role in meeting the rising demand for precision radiotherapy nationally and internationally."


The directors of Proton Partners International Limited accept responsibility for this announcement.


Proton Partners International Limited

Mike Moran, Chief Executive Officer                                                                                  Tel: +44 (0) 16 3381 0661

Grant Thornton UK LLP (Corporate Adviser)

Colin Aaronson/ Jamie Barklem/ Niall McDonald                                                                Tel: +44 (0) 20 7383 5100

Media House International

Ramsay Smith                                                                                    07788 414 856 or



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit